So you’re saying there’s a chance.

The FDA sure is with it’s approval this week of pembrolizumab for recurrent and/or metastatic cervical cancer failing at least one line of chemo. This is based on the underwhelming results of the phase 2 KEYNOTE-158 trial that recently released results on 77 patients, 2 of whom achieved a complete response and another 9 a partial response. | FDA 2018


Popular Posts